September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Elvina Almuradova: FDA approves Zanidatama for HER2+ biliary tract cancer
Nov 24, 2024, 18:03

Elvina Almuradova: FDA approves Zanidatama for HER2+ biliary tract cancer

Elvina Almuradova, Associate Professor at Medicana Health Group, shared a post on X:

FDA approves Zanidatama for HER2+ biliary tract cancer based on HERIZON-BTC-01 trial results:

  • ORR: 52%
  • DOR: 14.9 months
  • First dual HER2-targeted bispecific antibody for BTC

The confirmatory Phase III trial is ongoing.”

Elvina Almuradova: FDA approves Zanidatama for HER2+ biliary tract cancer

Read more about the FDA approval of Zanidatama on oncodaily.com.

More posts featuring Elvina Almuradova.